262438-43-7 | Atn-161

Packsize	Purity	Availability	Price	Discounted Price
1mg	98%	in stock	$18.00	$12.00
5mg	98%	in stock	$29.00	$20.00
10mg	98%	in stock	$40.00	$28.00
50mg	98%	in stock	$100.00	$70.00

Description

• Catalog Number: AF32535
• Chemical Name: Atn-161
• CAS Number: 262438-43-7
• Molecular Formula: C23H35N9O8S
• Molecular Weight: 597.6445
• MDL Number: MFCD30478885
• SMILES: OC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N)CC(=O)N)CS)NC(=O)[C@@H](NC(=O)[C@@H]1CCCN1C(=O)C)Cc1nc[nH]c1

Computed Properties

• Complexity: 1020
• Covalently-Bonded Unit Count: 1
• Defined Atom Stereocenter Count: 5
• Heavy Atom Count: 41
• Hydrogen Bond Acceptor Count: 10
• Hydrogen Bond Donor Count: 9
• Rotatable Bond Count: 15
• XLogP3: -4.7

Literature

• Therapeutic inhibition of breast cancer bone metastasis progression and lung colonization: breaking the vicious cycle by targeting α5β1 integrin.

  Breast cancer research and treatment 20160601

• The antiangiogenic effects of integrin alpha5beta1 inhibitor (ATN-161) in vitro and in vivo.

  Investigative ophthalmology & visual science 20110914

• Increased potency of the PHSCN dendrimer as an inhibitor of human prostate cancer cell invasion, extravasation, and lung colony formation.

  Clinical & experimental metastasis 20100301

• Pharmacology of the novel antiangiogenic peptide ATN-161 (Ac-PHSCN-NH2): observation of a U-shaped dose-response curve in several preclinical models of angiogenesis and tumor growth.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20080401

• Angiogenesis blockade as a new therapeutic approach to experimental colitis.

  Gut 20070601

• A non-RGD-based integrin binding peptide (ATN-161) blocks breast cancer growth and metastasis in vivo.

  Molecular cancer therapeutics 20060901

• Phase 1 trial of the antiangiogenic peptide ATN-161 (Ac-PHSCN-NH(2)), a beta integrin antagonist, in patients with solid tumours.

  British journal of cancer 20060605

• Effect of physicochemical modification on the biodistribution and tumor accumulation of HPMA copolymers.

  Journal of controlled release : official journal of the Controlled Release Society 20051210

• Inhibition of integrin alpha5beta1 function with a small peptide (ATN-161) plus continuous 5-FU infusion reduces colorectal liver metastases and improves survival in mice.

  International journal of cancer 20030420

• Suppression of tumor recurrence and metastasis by a combination of the PHSCN sequence and the antiangiogenic compound tetrathiomolybdate in prostate carcinoma.

  Neoplasia (New York, N.Y.) 20020901